secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001193125-24-223242
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones
--------------------------------------------------------------------------------

- FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.
- XOMA is entitled to a mid-single digit royalty on commercial sales of MIPLYFFA.
- XOMA may receive up to $52.6 million (net) in milestone payments from Zevra.
- MIPLYFFA is the sixth commercial asset in XOMA's royalty and milestone portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524223242/0001193125-24-223242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524223242/d836129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-223242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer